Virtual Trials Webinar

– On demand by filling out the form on the right

Patients have started to become reluctant to visit sites due to COVID-19, and studies must change to accommodate this. This development is pushing for a faster adaptation of virtual trials, either fully or partially.   

The webinar will focus on the advantages of virtual trials, and how virtual trials enable the study to get closer to the patients. We will go through the typical components in a virtual trial, both the internal processes, the services needed and the technology. 

Patient engagement, the devices used (incl. smartphone apps), eCOA/eDiary, eConsent and mobile data collection will be covered in the webinar. We will also go through the typical services needed in order to roll out to patients and how to avoid patient selection bias. 

After the webinar you will know how to get started with the planning of virtual trials.

    You must agree before submitting.

    For more information on how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

    Input this code: captcha

    Speakers

    Sophie Hytteballe

    Sophie Hytteballe

    Senior Project Manager

    Sophie is a Senior Project Manager specialized within eClinical Analysis and strategy. Sophie has a background in research combined with diverse experience across the clinical systems and a deep understanding of the clinical landscape and its interfaces, especially with CTMS, EDC, MDR, SCE and CDW. Previous experience includes planning and executing complex clinical projects, as well as vendor and stakeholder management.
    John Aggerholm

    John Aggerholm

    Project Director

    John is a life sciences industry veteran, with over 30 years of experience working in the pharmaceutical world. Working as a Project Director, his experience includes multiple clinical systems analysis and implementation projects. Recently, John has focused on Virtual Trials and has helped multiple of our pharmaceutical clients develop and implement Decentralized Trial Frameworks.